DE69433775D1 - Bioabbaubare partikeln - Google Patents

Bioabbaubare partikeln

Info

Publication number
DE69433775D1
DE69433775D1 DE69433775T DE69433775T DE69433775D1 DE 69433775 D1 DE69433775 D1 DE 69433775D1 DE 69433775 T DE69433775 T DE 69433775T DE 69433775 T DE69433775 T DE 69433775T DE 69433775 D1 DE69433775 D1 DE 69433775D1
Authority
DE
Germany
Prior art keywords
particles
injectable
injectable particles
biodegradable particles
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433775T
Other languages
English (en)
Other versions
DE69433775T2 (de
Inventor
Ruxandra Gref
Yoshiharu Minamitake
S Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/096,370 external-priority patent/US5543158A/en
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of DE69433775D1 publication Critical patent/DE69433775D1/de
Application granted granted Critical
Publication of DE69433775T2 publication Critical patent/DE69433775T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2300/00—Characterised by the use of unspecified polymers
    • C08J2300/16—Biodegradable polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2371/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
    • C08J2371/02—Polyalkylene oxides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
DE69433775T 1993-07-23 1994-07-22 Bioabbaubare Partikel Expired - Fee Related DE69433775T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/096,370 US5543158A (en) 1993-07-23 1993-07-23 Biodegradable injectable nanoparticles
US96370 1993-07-23
US210677 1994-03-18
US08/210,677 US5565215A (en) 1993-07-23 1994-03-18 Biodegradable injectable particles for imaging
PCT/US1994/008416 WO1995003357A1 (en) 1993-07-23 1994-07-22 Biodegradable particles

Publications (2)

Publication Number Publication Date
DE69433775D1 true DE69433775D1 (de) 2004-06-17
DE69433775T2 DE69433775T2 (de) 2005-04-14

Family

ID=26791633

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433775T Expired - Fee Related DE69433775T2 (de) 1993-07-23 1994-07-22 Bioabbaubare Partikel

Country Status (7)

Country Link
US (2) US5565215A (de)
EP (1) EP0710261B1 (de)
JP (1) JPH09504042A (de)
AT (1) ATE266695T1 (de)
CA (1) CA2167921C (de)
DE (1) DE69433775T2 (de)
WO (1) WO1995003357A1 (de)

Families Citing this family (407)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
EP0862419B2 (de) 1995-11-09 2010-11-17 Microbiological Research Authority Mikroverkapselte dna zur impfung und gentherapie
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
WO1997032609A2 (en) * 1996-03-05 1997-09-12 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
EP0935415B1 (de) 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
ES2289188T3 (es) 1996-09-11 2008-02-01 Bristol-Myers Squibb Medical Imaging, Inc. Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
WO1998018498A2 (en) * 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
DE69838669T2 (de) * 1997-04-30 2008-10-30 Point Biomedical Corp., San Carlos Mikropartikel, geeignet als kontrastmittel im ultraschall und zur wirkstoffgabe in den blutkreislauf
US20020159951A1 (en) * 1997-05-06 2002-10-31 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6275726B1 (en) * 1997-05-15 2001-08-14 Board Of Regents, The University Of Texas System Methods of enhanced light transmission through turbid biological media
US6045777A (en) * 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6165440A (en) * 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6211249B1 (en) * 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6254890B1 (en) * 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
JP2001525470A (ja) * 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19813174A1 (de) * 1998-03-25 1999-05-27 Schering Ag Mikropartikel aus Polymeren und mindestens einer gerüstbildenden Komponente und ihre Herstellung und Verwendung in der Ultraschalldiagnostik und zur ultraschallinduzierten Wirkstofffreisetzung
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
IL139541A0 (en) * 1998-05-20 2004-02-08 Liposome Co Inc Novel particulate formulations
AU764001B2 (en) 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US7343710B2 (en) * 1998-07-03 2008-03-18 I.D.A Limited Method and apparatus for controlling pests
GB9814507D0 (en) * 1998-07-03 1998-09-02 Univ Southampton A method and apparatus for controlling pests
US6179862B1 (en) 1998-08-14 2001-01-30 Incept Llc Methods and apparatus for in situ formation of hydrogels
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
JP4159254B2 (ja) * 1998-08-14 2008-10-01 インセプト エルエルシー ヒドロゲルのインサイチュ形成のための方法および装置
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
WO2000029206A1 (en) * 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
CA2349203C (en) 1998-11-20 2013-05-21 Rtp Pharma Inc. Dispersible phospholipid stabilized microparticles
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE19921088C2 (de) * 1999-04-30 2003-08-07 Magforce Applic Gmbh Stent zur Offenhaltung gangartiger Strukturen
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6426145B1 (en) 1999-05-20 2002-07-30 Scimed Life Systems, Inc. Radiopaque compositions for visualization of medical devices
AU5218500A (en) * 1999-06-22 2001-01-09 Aventis Research & Technologies Gmbh & Co. Kg Stable, radioactively marked nanoparticles, method for the production and utilization thereof
DE19930729A1 (de) * 1999-07-05 2001-01-11 Achim Goepferich Blockcopolymere zur Herstellung biomimetischer Oberflächen
EP1202670A4 (de) * 1999-08-13 2004-11-10 Point Biomedical Corp Hohle mikrokugeln mit kontrollierter zerbrechlichkeit zur medizinischen verwendung
WO2001012071A1 (en) * 1999-08-13 2001-02-22 Point Biomedical Corporation Microparticles useful as ultrasonic contrast agents and for lymphatic system
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
AU2001247417A1 (en) * 2000-03-14 2001-09-24 Trustees Of Tufts College Cross-reactive sensors
FR2809112B1 (fr) * 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
EP1341497A4 (de) * 2000-11-02 2005-10-19 Smithkline Beecham Corp Rezeptor-antagonisten-lipid-konjugate und diese enthaltende abgabeträger
EP1343973B2 (de) 2000-11-16 2020-09-16 California Institute Of Technology Vorrichtung und verfahren zur durchführung von assays und screening mit hohem durchsatz
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US8137699B2 (en) * 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
KR100463167B1 (ko) * 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US7153703B2 (en) * 2001-05-14 2006-12-26 Board Of Trustees Of The University Of Arkansas N. A. Synthesis of stable colloidal nanocrystals using organic dendrons
AU2002303869B2 (en) * 2001-05-21 2007-08-16 Novartis Ag Pulmonary administration of chemically modified insulin
AU2002320058A1 (en) * 2001-06-06 2002-12-16 The General Hspital Corporation Magnetic-nanoparticle conjugates and methods of use
US6955888B2 (en) * 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
AU2002322289A1 (en) * 2001-06-22 2003-01-08 Johns Hopkins University School Of Medicine Biodegradable polymer coompositions
WO2003017987A1 (en) * 2001-08-31 2003-03-06 Mcgill University Biodegradable polymeric nanocapsules and uses thereof
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
CA2463172C (en) * 2001-10-18 2009-08-18 Samyang Corporation Polymeric micelle composition with improved stability
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US6919068B2 (en) * 2002-05-17 2005-07-19 Point Biomedical Corporation Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging
US7670623B2 (en) 2002-05-31 2010-03-02 Materials Modification, Inc. Hemostatic composition
US7297348B2 (en) * 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
FR2842737B1 (fr) * 2002-07-25 2006-01-27 Centre Nat Rech Scient Particules revetues en surface de hyaluronane ou d'un de ses derives et leur utilisation a titre de vecteurs biologiques pour des matieres actives
US20040028804A1 (en) * 2002-08-07 2004-02-12 Anderson Daniel G. Production of polymeric microarrays
WO2004065362A2 (en) * 2002-08-16 2004-08-05 University Of Massachusetts Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation
WO2004031732A2 (en) 2002-10-03 2004-04-15 The Board Of Trustees Of The University Of Arkansas Nanocrystals in ligand boxes exhibiting enhanced chemical, photochemical, and thermal stability, and methods of making the same
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
US7094730B2 (en) * 2002-10-31 2006-08-22 Delphi Technologies, Inc. Gas treatment device, methods for making and using the same, and a vehicle exhaust system
US20040086432A1 (en) * 2002-10-31 2004-05-06 Labarge William J. Reformer, systems utilizing the reformer, and methods for operating the systems
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7007972B1 (en) 2003-03-10 2006-03-07 Materials Modification, Inc. Method and airbag inflation apparatus employing magnetic fluid
US20040185108A1 (en) * 2003-03-18 2004-09-23 Short Robert E. Method of preparing gas-filled polymer matrix microparticles useful for delivering drug
US7645512B1 (en) * 2003-03-31 2010-01-12 The Research Foundation Of The State University Of New York Nano-structure enhancements for anisotropic conductive adhesive and thermal interposers
US8518304B1 (en) 2003-03-31 2013-08-27 The Research Foundation Of State University Of New York Nano-structure enhancements for anisotropic conductive material and thermal interposers
EP1620079A1 (de) * 2003-04-03 2006-02-01 Semafore Pharmaceuticals, Inc. Knochen-targeting von biologisch abbaubaren arzneimittelhaltigen nanoteilchen
AU2004233870B2 (en) * 2003-04-24 2009-11-05 The Board Of Regents Of The University Of Texas System Noninvasive blood analysis by optical probing of the veins under the tongue
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
US6982501B1 (en) 2003-05-19 2006-01-03 Materials Modification, Inc. Magnetic fluid power generator device and method for generating power
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
WO2005002643A2 (en) * 2003-06-24 2005-01-13 Johns Hopkins University Method and products for delivering biological molecules to cells using multicomponent nanostructures
ES2232287B1 (es) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de derivados polioxietilenados.
US7200956B1 (en) 2003-07-23 2007-04-10 Materials Modification, Inc. Magnetic fluid cushioning device for a footwear or shoe
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US20050042298A1 (en) * 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
US20050136536A1 (en) * 2003-09-15 2005-06-23 Anderson Daniel G. Embryonic epithelial cells
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
US20050084513A1 (en) * 2003-10-21 2005-04-21 Board Of Regents Nanocoating for improving biocompatibility of medical implants
JP2007509989A (ja) 2003-10-31 2007-04-19 ポイント バイオメディカル コーポレイション 超音波造影剤として有用な再構成可能なミクロスフィア組成物
US7608240B2 (en) * 2003-12-05 2009-10-27 Board Of Trustees Of The University Of Arkansas Nanotubes for cancer therapy and diagnostics
US20080305048A1 (en) * 2003-12-10 2008-12-11 The General Hospital Corporation Self-Assembling Nanoparticle Conjugates
EP1713514B1 (de) * 2004-01-28 2021-11-24 Johns Hopkins University Arzneimittel und genträgerteilchen, die sich schnell durch schleimhautbarrieren bewegen
EP1711163A2 (de) * 2004-02-05 2006-10-18 Baxter International Inc. Unter verwendung von selbststabilisierenden mitteln hergestellte dispersionen
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US7632784B2 (en) * 2004-04-17 2009-12-15 Rokhvarger Anatoly E Sintered ceramic composite lead with superconductive nano-architecture
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
EP1786443B1 (de) * 2004-07-19 2018-06-06 Celator Pharmaceuticals, Inc. Teilchenförmige konstrukte zur freisetzung von wirkstoffen
US8357391B2 (en) * 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
CA2581190A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
US9492400B2 (en) * 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US8394410B2 (en) * 2005-01-20 2013-03-12 Massachusetts Institute Of Technology Soft polylactides
US7611494B2 (en) * 2005-02-08 2009-11-03 Confluent Surgical, Inc. Spray for fluent materials
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
EP1866155A2 (de) * 2005-04-05 2007-12-19 Bar-Ilan University Neue kern- und kern-schale-nanopartikel mit iod für die röntgenabbildung
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
KR100806669B1 (ko) 2005-06-23 2008-02-26 김정환 나노 입자-생체 복합체
JP2009502261A (ja) * 2005-07-25 2009-01-29 ナノテクノロジー ビクトリア ピーティーワイ リミテッド マイクロアレイデバイス
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US7564245B2 (en) 2005-08-31 2009-07-21 T2 Biosystems, Inc. NMR device for detection of analytes
KR100718329B1 (ko) * 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
US20070264199A1 (en) * 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
US20070071683A1 (en) * 2005-09-27 2007-03-29 The Regents Of The University Of California Ultrasonic concentration of carrier particles
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
US20070156230A1 (en) 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
AU2013205838B2 (en) * 2006-02-21 2016-03-17 Avrum Belzer Hyperpolarization Methods, Systems and Compositions
KR101095943B1 (ko) * 2006-02-21 2011-12-19 밀리켈빈 테크놀로지스 엘엘씨 과분극화 방법, 시스템 및 조성물
EP1988928A4 (de) * 2006-02-24 2011-11-16 Univ Yonsei Iacf Magnetische nanocomposite für kontrastmittel, intelligentes kontrastmittel, arzneimittelabgabemittel zur gleichzeitigen diagnose und behandlung und trennmittel für zielsubstanz
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
US20070225472A1 (en) * 2006-03-23 2007-09-27 Varshney Sunil K Polyanhydride polymers and their uses in biomedical devices
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US20130325104A1 (en) 2006-05-26 2013-12-05 Abbott Cardiovascular Systems Inc. Stents With Radiopaque Markers
WO2007143698A2 (en) 2006-06-06 2007-12-13 Rutgers, The State University Of New Jersey Iodinated polymers
US8535372B1 (en) 2006-06-16 2013-09-17 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with prohealing layer
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8128688B2 (en) 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US7823263B2 (en) 2006-07-11 2010-11-02 Abbott Cardiovascular Systems Inc. Method of removing stent islands from a stent
EP3047860A1 (de) 2006-07-20 2016-07-27 OrbusNeich Medical, Inc. Bioresorbierbare polymerzusammensetzung für eine medizinische vorrichtung
US8016879B2 (en) 2006-08-01 2011-09-13 Abbott Cardiovascular Systems Inc. Drug delivery after biodegradation of the stent scaffolding
ES2532595T3 (es) * 2006-08-30 2015-03-30 Kyushu University, National University Corporation Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
EP2061433B1 (de) * 2006-09-08 2011-02-16 Johns Hopkins University Zusammensetzungen zur transportintensivierung durch die schleimhaut
EP2086513B1 (de) * 2006-09-26 2016-09-07 Samyang Biopharmaceuticals Corporation Submikron-nanoteilchen von schwer wasserlöslichen camptothecin-derivaten und herstellungsverfahren dafür
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
CA2667325A1 (en) * 2006-10-23 2008-05-02 Bioabsorbable Therapeutics, Inc. A drug-release composition having a therapeutic carrier
US8636787B2 (en) * 2006-10-25 2014-01-28 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
US10149935B2 (en) * 2006-11-27 2018-12-11 Frank Levy Delivery system and method for the effective and reliable delivery of controlled amounts of a medical fluid
US11712510B2 (en) 2006-11-27 2023-08-01 Frank Levy Delivery system and method for the effective, reliable and foolproof delivery of controlled amounts of a medical fluid
US20100015050A1 (en) * 2006-12-21 2010-01-21 Wayne State University Peg and targeting ligands on nanoparticle surface
KR100809402B1 (ko) 2007-01-29 2008-03-05 김정환 나노 입자 표지, 나노 입자 표지를 이용하는 진단 키트, 및진단 방법
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US8889117B2 (en) 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2431043A1 (de) 2007-05-23 2012-03-21 Amcol International Corporation Mit Cholesterin interagierende Phyllosilikate zur Unterdrückung der gastrointestinalen Cholesterinabsorption
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US7901452B2 (en) 2007-06-27 2011-03-08 Abbott Cardiovascular Systems Inc. Method to fabricate a stent having selected morphology to reduce restenosis
US7955381B1 (en) 2007-06-29 2011-06-07 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
WO2009012372A1 (en) 2007-07-18 2009-01-22 Advantageous Systems, Llc Methods and apparatuses for detecting analytes in biological fluid of an animal
WO2009026164A1 (en) * 2007-08-17 2009-02-26 The General Hospital Corporation Magnetic resonance-based viscometers and methods
SG150405A1 (en) * 2007-08-29 2009-03-30 Agency Science Tech & Res Method of coating a particle
HUE035101T2 (hu) 2007-09-28 2018-05-02 Pfizer Ráksejtek célzása nanorészecskék alkalmazásával
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US20110027172A1 (en) * 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
CN102105554A (zh) * 2008-06-10 2011-06-22 阿肯色大学托管委员会 砷化铟纳米晶体及其制备方法
PT2774608T (pt) 2008-06-16 2020-01-17 Pfizer Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US20100055041A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nanotracer for in-situ gastric cancer detection
WO2010039865A2 (en) * 2008-10-01 2010-04-08 Cornell University Biodegradable chemical delivery system
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
WO2010068866A2 (en) * 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US8580230B2 (en) * 2009-02-23 2013-11-12 Kent State University Materials and methods for MRI contrast agents and drug delivery
EP2413901A4 (de) * 2009-03-30 2015-05-06 Cerulean Pharma Inc Polymerstoffkonjugate, partikel, zusammensetzungen und entsprechende verwendungsverfahren
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010117957A2 (en) 2009-04-06 2010-10-14 Mayo Foundation For Medical Education And Research Methods and materials for delivering molecules
JP6297776B2 (ja) 2009-05-27 2018-03-20 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 免疫調節薬−高分子化合物
US20110110965A1 (en) 2009-08-26 2011-05-12 Selecta Biosciences, Inc. Compositions that induce t cell help
US9205155B2 (en) 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
CA3042067C (en) * 2009-12-15 2022-10-18 Incept, Llc Implants and biodegradable fiducial markers
EP2512487A4 (de) * 2009-12-15 2013-08-07 Therapeutische polymernanopartikel mit corticosteroiden sowie verfahren zu deren herstellung und verwendung
EP2512522A4 (de) * 2009-12-16 2013-09-25 Brigham & Womens Hospital Partikel zur abgabe mehrerer wirkstoffe
US9089512B2 (en) 2009-12-18 2015-07-28 President And Fellows Of Harvard College Active scaffolds for on-demand drug and cell delivery
EP2523680A4 (de) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
AU2011230601B2 (en) * 2010-03-26 2015-04-02 Evonik Corporation Emulsions for microencapsulation comprising biodegradable surface-active block copolymers as stabilizers
US8808357B2 (en) * 2010-04-06 2014-08-19 Poly-Med, Inc. Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof
EP2575876B1 (de) 2010-05-26 2017-12-06 Selecta Biosciences, Inc. Multivalente synthetische nanoträger-impfstoffe
US9364568B2 (en) * 2010-07-15 2016-06-14 Warsaw Orthopedic, Inc. Methods to diagnose degenerative disc disease
JP5655147B2 (ja) * 2010-08-20 2015-01-14 セルリアン・ファーマ・インコーポレイテッド 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法
KR20130100290A (ko) 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CA3155334A1 (en) 2010-10-22 2012-04-26 T2 Biosystems, Inc. NMR SYSTEMS AND METHODS FOR RAPID ANALYTE DETECTION
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
WO2012105984A1 (en) * 2011-02-04 2012-08-09 Empire Technology Development Llc Materials, monitoring, and controlling tissue growth using magnetic nanoparticles
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9713702B2 (en) * 2011-03-14 2017-07-25 The Board Of Trustee Of The Leland Stanford Junior University Methods of electric field induced delivery of compounds, compositions used in delivery, and systems of delivery
KR102112002B1 (ko) 2011-04-29 2020-05-18 셀렉타 바이오사이언시즈, 인크. 치료적 단백질에 대해 면역 반응을 감소시키는 관용원성 합성 나노운반체
US9801829B2 (en) * 2011-04-29 2017-10-31 University Of Florida Research Foundation, Inc. Methods and systems of making nanostructures
EP2706989A1 (de) * 2011-05-09 2014-03-19 Instituto Químico De Sarrià Polymere nanopartikel zur wirkstofffreisetzung
CA2842321C (en) 2011-07-18 2022-05-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CN104936620B (zh) 2012-01-19 2019-08-09 约翰霍普金斯大学 增强粘膜渗透的纳米粒子调配物
US8927529B2 (en) 2012-01-30 2015-01-06 SpineThera Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer
US20130236504A1 (en) 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
EP3524692A1 (de) 2012-04-20 2019-08-14 T2 Biosystems, Inc. Zusammensetzungen und verfahren zur detektion der candida-spezies
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP4008355A1 (de) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmazeutische nanopartikel mit verbessertem mukosalem transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
EP2849728A1 (de) 2012-05-04 2015-03-25 The Johns Hopkins University Arzneimittelträger auf lipidbasis zur schnellen penetration durch schleimauskleidungen
MX356097B (es) 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
CN103830741B (zh) * 2012-11-27 2019-02-19 杨子剑 含有陶扎色替类似物结构的化合物以及制备方法和用途
CN103848901A (zh) * 2012-11-28 2014-06-11 杨子剑 含有万古霉素结构的新化合物以及制备方法和用途
CN103848986B (zh) * 2012-11-28 2019-10-11 杨子剑 含有头孢菌素结构的化合物以及制备方法和用途
CN103848894A (zh) * 2012-11-30 2014-06-11 杨子剑 含有达托霉素结构的新化合物以及制备方法和用途
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
CN105339012A (zh) 2013-05-03 2016-02-17 西莱克塔生物科技公司 降低i型和iv型超敏反应的致耐受性合成纳米载体的局部伴随施用
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
CN112933218A (zh) 2013-06-04 2021-06-11 西莱克塔生物科技公司 非免疫抑制性抗原特异性免疫治疗剂的重复施用
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN105037710A (zh) * 2013-09-01 2015-11-11 韩冰 新化合物的制备方法及其在医疗中的新用途
ES2640648T3 (es) 2013-09-16 2017-11-03 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
MX2016016507A (es) 2014-06-12 2017-04-27 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
AU2015280417B2 (en) 2014-06-24 2020-01-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
AU2015279738A1 (en) 2014-06-25 2016-12-22 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
US10557848B2 (en) 2014-09-02 2020-02-11 Lsi Medience Corporation Polymer microparticle for carrying physiologically active substance and method for preparing same
CA2957800A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
ES2865375T3 (es) 2014-11-05 2021-10-15 Selecta Biosciences Inc Métodos y composiciones relacionadas con nanovehículos sintéticos con rapamicina en un estado sobresaturado estable
JP6882186B2 (ja) 2014-12-15 2021-06-02 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
EP3250184A1 (de) 2015-01-27 2017-12-06 The Johns Hopkins University Hypotone hydrogelformulierungen für den verbesserten transport von wirkstoffen an schleimhautoberflächen
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US9737368B2 (en) 2015-02-24 2017-08-22 Abbott Cardiovascular Systems Inc. System and method for attaching a radiopaque marker bead to an endoprosthesis
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
US9700443B2 (en) 2015-06-12 2017-07-11 Abbott Cardiovascular Systems Inc. Methods for attaching a radiopaque marker to a scaffold
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
WO2017075565A1 (en) * 2015-10-30 2017-05-04 The Johns Hopkins University Mucus penetrating particles with high molecular weight and dense coatings
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
JP2019504027A (ja) 2015-12-22 2019-02-14 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
CA3011901A1 (en) 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
CN115969970A (zh) 2016-02-10 2023-04-18 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan的组合
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20170258927A1 (en) 2016-03-11 2017-09-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CN105859933B (zh) * 2016-03-31 2018-09-21 北京化工大学 一种具有核壳结构的反应型聚合物微球及其制备方法和应用
CN109310385A (zh) 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
MX2019000200A (es) 2016-07-01 2019-09-26 G1 Therapeutics Inc Agentes antiproliferativos basados en pirimidina.
CN109922819A (zh) 2016-09-27 2019-06-21 西莱克塔生物科技公司 用于治疗癌症的重组免疫毒素
WO2018094227A1 (en) 2016-11-17 2018-05-24 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidine analogs and methods of making and using same
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US20190112731A1 (en) 2017-10-12 2019-04-18 Julianne Holloway Manufacturing gradient materials using magnetically-assisted electrospinning
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
EP3470056B1 (de) 2017-10-16 2022-04-27 Medtronic Vascular Inc. Therapeutische nanopartikel zur behandlung von gefässerkrankungen
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CA3099440A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
EP3823676A1 (de) 2018-07-16 2021-05-26 Selecta Biosciences, Inc. Verfahren und zusammensetzungen von mma-konstrukten und vektoren
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3866773A4 (de) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
US10987315B1 (en) 2018-12-04 2021-04-27 University Of South Florida Antithrombotic nanoparticles and methods for treating necrotizing enterocolitis
WO2020148206A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
US11471412B1 (en) 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
EP3976802A1 (de) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Verfahren und zusammensetzungen für abgeschwächte immunantwort auf antivirale transfervektoren
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
US20210154324A1 (en) 2019-10-21 2021-05-27 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
JP2023501457A (ja) 2019-11-08 2023-01-18 セレクタ バイオサイエンシーズ インコーポレーテッド ペグ化ウリカーゼの処方物および用量
CN115379839A (zh) 2020-02-26 2022-11-22 西莱克塔生物科技公司 使用包含免疫抑制剂的合成纳米载体的方法和组合物
BR112022018070A2 (pt) 2020-03-11 2022-10-25 Selecta Biosciences Inc Métodos e composições relacionados a nanoveículos sintéticos
MX2022012916A (es) 2020-04-14 2023-01-30 Selecta Biosciences Inc Métodos y composiciones para inducir la autofagia.
WO2022072348A1 (en) 2020-09-29 2022-04-07 Oxford University Innovation Limited Stroke treatment
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
CA3237037A1 (en) 2021-11-14 2023-05-19 Cartesian Therapeutics, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
FR2678178A1 (fr) * 1991-06-28 1992-12-31 Rhone Poulenc Rorer Sa Procede de preparation de nanoparticules.
FR2678168B1 (fr) * 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
CA2087125A1 (en) * 1992-01-23 1993-07-24 Mridula Nair Chemically fixed micelles
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition

Also Published As

Publication number Publication date
ATE266695T1 (de) 2004-05-15
CA2167921C (en) 2005-10-11
CA2167921A1 (en) 1995-02-02
WO1995003357A1 (en) 1995-02-02
EP0710261A1 (de) 1996-05-08
DE69433775T2 (de) 2005-04-14
US5578325A (en) 1996-11-26
US5565215A (en) 1996-10-15
JPH09504042A (ja) 1997-04-22
EP0710261B1 (de) 2004-05-12

Similar Documents

Publication Publication Date Title
ATE266695T1 (de) Bioabbaubare partikeln
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
EP1820862A3 (de) Medizinische Präparate zur Behandlung von Alpha-Galaktosidase-A-Mangel
DK1125577T3 (da) Væskeformige medikamentindföringspræparater
RU93052890A (ru) Способ измельчения фармацевтических веществ
NO903608L (no) Middel for behandling av sterke smertetilstander og fremgangsmaate ved fremstilling derav.
EP0951917A3 (de) Teilchenverabreichung, insbesondere von therapeutischen Mitteln im pulverisierten Zustand
IS5415A (is) Gataðar öreiningar og aðferðir til notkunar þeirra
EP0602700A3 (de) Nanopartikeln enthaltende Röntgenkontrastmittel mit hochmolekularen Tensiden.
FI971776A (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
IL126179A (en) Pharmaceutical compositions containing anti-tumor drug conjugates
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
NO951138D0 (no) Mikropartikkelpreparater fremstilt fra biologisk nedbrytbare blandingspolymerer
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
GR3025596T3 (en) Compositions and methods for identifying biologically active molecules.
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
BG104020A (en) Pharmaceutical composition for mucous membrane application
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
DK1007082T3 (da) Modificeret tumor nekrose faktor
ZA954099B (en) Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
Shinoda et al. In vivo fate of folate–BSA in non‐tumor‐and tumor‐bearing mice
BR0014877A (pt) Veìculo magnético objetivado composto de ferro e materiais porosos para a distribuição objetivada de agentes biologicamente ativos
CA2273272A1 (en) Immediate release drug delivery forms
JPS5750914A (en) Betamethasone external pharmaceutical

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee